secukinumab,IL-17A:

Kouzhu Zhu1, Zhou Lu2, Lei Cao3

  • 1Department of Pharmacy, Affiliated Children's Hospital to Jiangnan University (Wuxi Children's Hospital), Jiangsu Wuxi, China.

PubMed
概括

高于35.43微克/毫升的secukinumab水平与牛皮患者的最佳反应有关. 较高的体重和较低的白蛋白可能会降低药物水平,需要调整剂量以有效治疗牛皮.